Citius Oncology (NASDAQ:CTOR) Announces Earnings Results

Citius Oncology (NASDAQ:CTOR) posted its quarterly earnings data on Friday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), FiscalAI reports. The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $2.50 million.

Citius Oncology Stock Up 10.0%

Shares of CTOR opened at $0.91 on Friday. The firm has a market capitalization of $84.59 million, a P/E ratio of -1.94 and a beta of 3.48. Citius Oncology has a 12-month low of $0.49 and a 12-month high of $2.25. The company has a current ratio of 0.50, a quick ratio of 0.12 and a debt-to-equity ratio of 0.11. The firm has a fifty day moving average price of $0.68 and a 200-day moving average price of $0.82.

Institutional Investors Weigh In On Citius Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares in the last quarter. Citadel Advisors LLC bought a new position in Citius Oncology in the third quarter worth approximately $36,000. Geode Capital Management LLC increased its holdings in Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after purchasing an additional 36,758 shares during the period. OMERS ADMINISTRATION Corp bought a new stake in Citius Oncology during the 4th quarter valued at $104,000. Finally, Jane Street Group LLC purchased a new stake in shares of Citius Oncology in the 2nd quarter worth $465,000. Institutional investors own 70.52% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Citius Oncology has an average rating of “Hold” and an average price target of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.